These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 32041717)

  • 1. Safety and Pharmacokinetic Characterization of Nacubactam, a Novel β-Lactamase Inhibitor, Alone and in Combination with Meropenem, in Healthy Volunteers.
    Mallalieu NL; Winter E; Fettner S; Patel K; Zwanziger E; Attley G; Rodriguez I; Kano A; Salama SM; Bentley D; Geretti AM
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32041717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and pharmacokinetics of single and multiple ascending doses of avibactam alone and in combination with ceftazidime in healthy male volunteers: results of two randomized, placebo-controlled studies.
    Merdjan H; Rangaraju M; Tarral A
    Clin Drug Investig; 2015 May; 35(5):307-17. PubMed ID: 25813217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Vaborbactam and Meropenem Alone and in Combination following Single and Multiple Doses in Healthy Adult Subjects.
    Rubino CM; Bhavnani SM; Loutit JS; Morgan EE; White D; Dudley MN; Griffith DC
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29437614
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Monogue ML; Giovagnoli S; Bissantz C; Zampaloni C; Nicolau DP
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 30012751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meropenem-nacubactam activity against AmpC-overproducing and KPC-expressing Pseudomonas aeruginosa in a neutropenic murine lung infection model.
    Asempa TE; Motos A; Abdelraouf K; Bissantz C; Zampaloni C; Nicolau DP
    Int J Antimicrob Agents; 2020 Feb; 55(2):105838. PubMed ID: 31705960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study assessing the safety, tolerability, and pharmacokinetics of avibactam and ceftazidime-avibactam in healthy Japanese volunteers.
    Tominaga N; Edeki T; Li J; Learoyd M; Bouw MR; Das S
    J Infect Chemother; 2015 Aug; 21(8):551-8. PubMed ID: 26076867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Human-Simulated Epithelial Lining Fluid Exposure of Meropenem-Nacubactam Combination against Class A Serine β-Lactamase-Producing
    Asempa TE; Motos A; Abdelraouf K; Bissantz C; Zampaloni C; Nicolau DP
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, Tolerability, Pharmacokinetics, and Drug Interaction Potential of SPR741, an Intravenous Potentiator, after Single and Multiple Ascending Doses and When Combined with β-Lactam Antibiotics in Healthy Subjects.
    Eckburg PB; Lister T; Walpole S; Keutzer T; Utley L; Tomayko J; Kopp E; Farinola N; Coleman S
    Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31262767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nacubactam Enhances Meropenem Activity against Carbapenem-Resistant Klebsiella pneumoniae Producing KPC.
    Barnes MD; Taracila MA; Good CE; Bajaksouzian S; Rojas LJ; van Duin D; Kreiswirth BN; Jacobs MR; Haldimann A; Papp-Wallace KM; Bonomo RA
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Randomized, Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of Ceftazidime-Avibactam in Healthy Chinese Subjects.
    Li J; Learoyd M; Qiu F; Zhu L; Edeki T
    Clin Drug Investig; 2016 Feb; 36(2):119-26. PubMed ID: 26649741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of nacubactam (RG6080/OP0595) combinations against MBL-producing Enterobacteriaceae.
    Mushtaq S; Vickers A; Woodford N; Haldimann A; Livermore DM
    J Antimicrob Chemother; 2019 Apr; 74(4):953-960. PubMed ID: 30590470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1 Study Assessing the Pharmacokinetic Profile and Safety of Avibactam in Patients With Renal Impairment.
    Merdjan H; Tarral A; Das S; Li J
    J Clin Pharmacol; 2017 Feb; 57(2):211-218. PubMed ID: 27402250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single- and multiple-dose study to determine the safety, tolerability, and pharmacokinetics of ceftaroline fosamil in combination with avibactam in healthy subjects.
    Riccobene TA; Su SF; Rank D
    Antimicrob Agents Chemother; 2013 Mar; 57(3):1496-504. PubMed ID: 23295928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-Center Evaluation of the Pharmacokinetics of WCK 5222 (Cefepime-Zidebactam Combination) in Subjects with Renal Impairment.
    Preston RA; Mamikonyan G; DeGraff S; Chiou J; Kemper CJ; Xu A; Mastim M; Yeole R; Chavan R; Patel A; Friedland HD; Bhatia A
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30397067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia.
    Qin X; Tran BG; Kim MJ; Wang L; Nguyen DA; Chen Q; Song J; Laud PJ; Stone GG; Chow JW
    Int J Antimicrob Agents; 2017 May; 49(5):579-588. PubMed ID: 28363526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, tolerability and pharmacokinetics of dalcetrapib following single and multiple ascending doses in healthy subjects: a randomized, double-blind, placebo-controlled, phase I study.
    Derks M; Anzures-Cabrera J; Turnbull L; Phelan M
    Clin Drug Investig; 2011; 31(5):325-35. PubMed ID: 21366361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single- and Multiple-Ascending-Dose Study of the Safety, Tolerability, and Pharmacokinetics of the Polymyxin Derivative SPR206.
    Bruss J; Lister T; Gupta VK; Stone E; Morelli L; Lei Y; Melnick D
    Antimicrob Agents Chemother; 2021 Sep; 65(10):e0073921. PubMed ID: 34339267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of age and sex on the pharmacokinetics and safety of avibactam in healthy volunteers.
    Tarral A; Merdjan H
    Clin Ther; 2015 Apr; 37(4):877-86. PubMed ID: 25769615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.